patient identification News
-
APP Imaging Workshop - A Collaborative Approach to mild Patient Selection
Interventional Pain Management is a fast-growing specialty. As new lumbar spinal stenosis (LSS) procedures become available, practices are evolving the way they collaborate and work together to optimize patient care. The mild® Procedure’s patient selection process is quite simple, but requires imaging review, which is often not a part of Advanced Practice Providers’ (APP) ...
-
Mainstay Medical Announces Limited Commercial Launch of ReActiv8 in the U.S.
Dublin – Ireland, 29 June 2021 – Mainstay Medical Holdings plc (the “Company”) today announced the limited commercial launch in the U.S. of ReActiv8, its implantable Restorative Neurostimulation™ system to treat intractable chronic low back pain. The ReActiv8 system will be available in the U.S. through ReActiv8-certified physicians commencing in the summer of ...
-
Longenesis joins Salto Growth Camp: EMERGEncy, a 100-hour online accelerator to address the COVID-19 crisis
Throughout this week Longenesis will be intensively working with mentors and investors (including Skype and Bolt co-Founders) to create and validate a concept for post-COVID-19 data utilization for research, faster drug development and patient recruitment. We believe that the tools developed by Longenesis have found a perfect fit in solving challenges in data and patient cohort identification ...
By Longenesis
-
Glycotest™ HCC Panel Completes Successful Clinical Product Evaluation
Glycotest Inc., announced today that it successfully completed a clinical evaluation of its HCC Panel in China. In a blinded evaluation of 149 HCC patient and control samples, the HCC Panel achieved an AUROC of 0.97. Glycotest is a private liver disease diagnostics company commercializing new and unique blood tests for liver cancers and fibrosis-cirrhosis. The Company’s mission is to ...
-
Forest Devices Announces Positive Study Results For Their Stroke Detection Technology
Medical technology pioneer Forest Devices, Inc. (FDI) today announced the publication of positive results from the EDGAR study of its AlphaStroke™ technology in identifying patients with large vessel occlusive (LVO) strokes in emergency departments in the American Heart Association Journal, STROKE. LVOs are the type of ischemic stroke that require an interventional thrombectomy, only ...
-
Brady introduces specimen labeling solution for histology and anatomic pathology labs
Brady Worldwide, Inc. (NYSE: BRC), a trusted provider for laboratory labeling, is pleased to introduce a new specimen labeling system for histology and anatomic pathology labs – the Brady Specimen Labeling Solution. With a revolutionary label attachment system and durable labels that withstand tissue processing and last up to 20 years in storage, Brady’s Specimen Labeling Solution is an ...
-
Longenesis and Medtronic Study Finds Insulin Pumps Contribute to Better Quality of Life for Type 1 Diabetes Patients
Longenesis announced today the preliminary results from its study on Type 1 Diabetes care in partnership with Medtronic. In less than three months, more than 85 patients participated in the research study, providing qualitative and quantitative data on the quality of life for Type 1 diabetics using insulin pumps compared to daily insulin injections. The study sponsors used participant data to ...
By Longenesis
-
Mozambique: technology revolution hits HIV testing and treatment
Delayed test results often mean HIV patients in Mozambique fail to get timely treatment, but new technology is reducing the need to send tests to far away laboratories, and speeding up test results and HIV treatment. Mozambique's Ministry of Health has increasingly begun experimenting with new technology to make diagnosing and monitoring HIV patients quicker and easier. After a successful 2009 ...
By SciDev.Net
-
STALICLA announces first patients enrolled in EU/US multicenter data collection biosampling study
The launch of the STA-B-001 study will accelerate the recruitment of participants for STP1 and STP2 Phase 2 trials. The multicenter trial will also enable deep clinical and biological data collection to strengthen STALICLA’s platform. Geneva, Switzerland – October 26th, 2022, STALICLA SA, a precision neuroscience clinical stage biotech, advancing the first precision medicine ...
By STALICLA
-
Infraredx, a Nipro Company, Announces Enrollment of First Patient in EXPANSE PTCA study.
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today the enrollment of the first patient in its EXPANSE PTCA study (NCT04985773) at the Cardiology Associates of North Mississippi in Tupelo, Mississippi. The study will be conducted in the United States with the objective to evaluate safety and effectiveness of the Lacrosse NSE ...
-
CD Genomics Launches Mature HLA Typing Solutions Enabling Precision Immune Profiling
CD Genomics, a renowned leader in genomics and next-generation sequencing (NGS) applications, has unveiled its cutting-edge HLA typing solutions, revolutionizing immune profiling and transplantation compatibility assessment. The human leukocyte antigen (HLA) system plays a crucial role in immune regulation and determining transplantation compatibility. HLA typing, the process of identifying ...
By CD Genomics
-
QuarkBio Announced its COVID-19 Test Kit 10 Times More Sensitive than Existing Kit
Quark Biosciences Inc. announced today the successful development of a novel digital PCR test, DigiChip SARS-CoV-2 Assay, that is 10x more sensitive than conventional diagnostic methods. The company plans to work with Shin Kong Memorial Hospital and a California-based medical group for clinical validation and to apply for regularly approval. The assay is capable of detecting ...
-
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy
Lausanne, Switzerland- March 25, 2020 - Debiopharm, a Swiss-based biopharmaceutical company announced today having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the development of their radioligand program, now called Debio 0228, which targets the CAIX (Carbonic Anhydrase 9) enzyme to fight the ...
-
V-Wave’s Interatrial Shunt Receives FDA Breakthrough Device Designation for Heart Failure
V-Wave Ltd., a privately held medical device company developing novel implantable interatrial shunt devices, today announced that the U.S. Food and Drug Administration (FDA) has just granted the company a Breakthrough Device Designation for its interatrial shunt for Heart Failure (HF). V-Wave’s minimally invasive, implanted interatrial shunt is being evaluated in a global, randomized, ...
By V-Wave Ltd.
-
Nyxoah Provides General Corporate Update
Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today provided a general corporate update. 2021 Highlights Implanted first U.S. patient in the DREAM IDE pivotal study in December 2020; there are currently ...
By Nyxoah SA
-
Infraredx, a Nipro Company, Announces FDA Approval of Expanded Label Claim for the Makoto Intravascular Imaging System
Infraredx, a Nipro Company, a pioneer in intravascular imaging for mapping coronary artery disease, announced today that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the indications for use for its Makoto Intravascular Imaging System. The approval is based on the results of the landmark Lipid-Rich Plaque (LRP) Study, which demonstrated the ability of ...
-
Research from Beacon Biosignals Presented at Alzheimer`s Association International Conference
Beacon Biosignals, a startup that applies AI to EEG to unlock precision medicine for neurological and psychiatric disorders, presented research at the Alzheimer's Association International Conference, which took place July 31–Aug. 4, 2022, in San Diego. Medical Director Jay Pathmanathan, MD, PhD, discussed how the company has applied its machine learning platform to standard ...
-
Anteris reports successful interim results for the first-in-human trial for DurAVR
Anteris Technologies Ltd (ASX: AVR) reports the first-in-human DurAVR™ THV study met or exceeded its interim study objectives. At the 30-day follow up point, the first five patients of the planned 10-patient study showed: All five subjects continued to do well with no reported adverse events (no death, stroke, myocardial infarction, reintervention). An average 86% improvement in mean ...
-
Endospan Enrolls First Patient in the TRIOMPHE IDE Study
Endospan, a pioneer in off-the-shelf endovascular repair of aortic arch disease, announces the first implant of the NEXUS™ Aortic Arch Stent Graft System on a patient with a thoracic aortic aneurysm as part of the TRIOMPHE Study in Norfolk, Virginia, January 11, 2021. The TRIOMPHE Study is a multi-arm, multi-center, non-randomized, prospective, clinical study to evaluate the safety and ...
-
Cerapedics Announces Canadian Approval of its next-generation bone graft
Cerapedics, a private ortho-biologics company, today announced the Health Canada approval of the company’s next-generation bone graft called i-FACTOR+ Matrix, making it the first market to approve the commercial launch of this product. “We are excited to announce Canadian regulatory approval of our next-generation product, based on P15 osteogenic cell-binding peptide , i-FACTOR+ ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you